Holen Sie sich die Stockscreener-App
2.99
2.40%
0.07
Vorhandelsmarkt:
2.99
Schlusskurs vom Vortag:
$2.92
Offen:
$2.93
24-Stunden-Volumen:
3.39M
Relative Volume:
0.95
Marktkapitalisierung:
$348.51M
Einnahmen:
$6.65M
Nettoeinkommen (Verlust:
$-136.32M
KGV:
-2.6052
EPS:
-1.1477
Netto-Cashflow:
$-112.04M
1W Leistung:
+23.55%
1M Leistung:
+51.01%
6M Leistung:
+196.04%
1J Leistung:
+166.96%
1-Tages-Spanne:
$2.84
$3.12
1-Wochen-Bereich:
$2.3834
$3.21
52-Wochen-Spanne:
$0.91
$3.21
Fate Therapeutics Inc Stock (FATE) Company Profile
Firmenname
Fate Therapeutics Inc
Sektor
Branche
Telefon
858.875.1803
Adresse
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Compare FATE vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
2.99 | 314.71M | 6.65M | -136.32M | -112.04M | -1.1477 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-05-19 | Fortgesetzt | Jefferies | Buy |
| 2025-10-31 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-10-27 | Hochstufung | Wedbush | Neutral → Outperform |
| 2024-11-18 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-06-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2023-01-24 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-01-06 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-01-06 | Herabstufung | Cowen | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-01-06 | Herabstufung | Stifel | Buy → Hold |
| 2023-01-06 | Herabstufung | Truist | Buy → Hold |
| 2023-01-06 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-12-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-12-15 | Eingeleitet | Goldman | Sell |
| 2022-11-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-10-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-07-28 | Eingeleitet | Needham | Hold |
| 2022-07-11 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-06-03 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-02-11 | Fortgesetzt | BMO Capital Markets | Market Perform |
| 2021-12-15 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-12-07 | Eingeleitet | Cowen | Outperform |
| 2021-11-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-26 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-06-07 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-05-07 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-04-26 | Fortgesetzt | Jefferies | Buy |
| 2021-02-26 | Eingeleitet | BofA Securities | Buy |
| 2021-02-26 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-02-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-01-27 | Fortgesetzt | H.C. Wainwright | Neutral |
| 2020-05-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-09 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2019-12-30 | Bestätigt | Mizuho | Buy |
| 2019-12-09 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-11-06 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2019-10-01 | Eingeleitet | Stifel | Buy |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-07-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-13 | Eingeleitet | Mizuho | Buy |
| 2019-06-07 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-31 | Eingeleitet | Guggenheim | Buy |
| 2019-05-24 | Fortgesetzt | Citigroup | Buy |
| 2019-03-28 | Eingeleitet | SVB Leerink | Outperform |
| 2019-01-03 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2018-11-05 | Eingeleitet | Jefferies | Buy |
| 2018-08-01 | Eingeleitet | Citigroup | Buy |
| 2018-03-06 | Herabstufung | H.C. Wainwright | Buy → Neutral |
Alle ansehen
Fate Therapeutics Inc Aktie (FATE) Neueste Nachrichten
Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences - The Manila Times
Fate Therapeutics lines up four investor conferences in Q3 - Stock Titan
Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 2000 Index - marketscreener.com
Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 3000E Index - marketscreener.com
Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 2000 Value Benchmark - marketscreener.com
Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 2000 Dynamic Index - marketscreener.com
Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 3000E Value Benchmark - marketscreener.com
Fate Therapeutics Stock Pops As FT836 Cancer Data Impress Traders - StocksToTrade
Fate Therapeutics Inc (FATE) Stock Price, Quote, News & History - Benzinga
F6T Forecast — Price Target — Prediction for 2027 - TradingView
Fate Therapeutics sets out next steps, biotech stock in focus after cash preservation move - AD HOC NEWS
Fate Therapeutics, Inc. Actuals & Estimates (DUS:F6T) - TradingView
Fate Therapeutics Inc (FATE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Fate Therapeutics, Inc. Actuals & Estimates (TRADEGATE:F6T) - TradingView
Fate Therapeutics, Inc. Actuals & Estimates (NASDAQ:FATE) - TradingView
Enterprise value to revenue forward of Fate Therapeutics, Inc. – NASDAQ:FATE - TradingView
Fate Therapeutics, Inc. Actuals & Estimates (FWB:F6T) - TradingView
Price to earnings forward of Fate Therapeutics, Inc. – NASDAQ:FATE - TradingView
FATE Forecast — Price Target — Prediction for 2027 - TradingView
Fate Therapeutics Inc (FATE) Institutional Confidence - TradingKey
H.C. Wainwright Maintains Fate Therapeutics(FATE.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Fate Therapeutics’s FT819 Progress Keeps My Bull Case Alive (NASDAQ:FATE) - Seeking Alpha
Fate Therapeutics Inc (FATE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Fate Therapeutics (FATE) Gets a Buy from Mizuho Securities - The Globe and Mail
Fate Therapeutics Inc (FATE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TRDA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Fate Therapeutics Inc (FATE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Fate Therapeutics Inc (FATE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Fate Therapeutics Inc (FATE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Fate Therapeutics Inc (FATE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Fate Therapeutics Inc (FATE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
FATE Stock Price, Quote & Chart - ChartMill
Fate Therapeutics Shareholders Back Directors and Governance Plans - The Globe and Mail
Redmile director nominee awarded 87,900 Fate Therapeutics (FATE) stock options - Stock Titan
Fate Therapeutics (FATE) director granted 87,900 stock options at $2.06 - Stock Titan
Director Yuan Xu receives 87,900 Fate Therapeutics (FATE) stock options at $2.06 - Stock Titan
FATE Therapeutics (NASDAQ: FATE) director awarded 87,900 stock options as equity pay - Stock Titan
Fate Therapeutics (FATE) director receives 87,900 stock options at $2.06 strike - Stock Titan
Fate Therapeutics (FATE) director receives 87,900 stock options award - Stock Titan
FATE Therapeutics (NASDAQ: FATE) director receives 87,900-share stock option grant - Stock Titan
Director at Fate Therapeutics (NASDAQ: FATE) receives 87,900 stock options grant - Stock Titan
Director Laura Hamill receives 175,800 Fate Therapeutics (FATE) stock options - Stock Titan
Director Laura Hamill files initial Form 3 for FATE Therapeutics (FATE) - Stock Titan
[8-K] FATE THERAPEUTICS INC Reports Material Event - Stock Titan
Fate Therapeutics Inc Stock (US3025491025): valuation focus as clinical-stage biotech trades near lo - Ad-hoc-news.de
Fate Therapeutics Appoints Laura Hamill To Board Of Directors - TradingView
Fate Therapeutics appoints Laura Hamill to board of directors - Investing.com
Fate Therapeutics appoints Laura Hamill to board of directors By Investing.com - Investing.com South Africa
Fate Therapeutics Appoints Laura Hamill to Board of Directors - The Manila Times
Fate Therapeutics, Inc. (FATE) Latest Stock News & Headlines - Yahoo Finance
Fate Therapeutics (FATE) Q1 2026 Earnings: EPS Beat on Cost Discipline, Pipeline Progress Drives Stock HigherSegment Revenue Breakdown - newsline.com
Finanzdaten der Fate Therapeutics Inc-Aktie (FATE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Fate Therapeutics Inc-Aktie (FATE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Valamehr Bahram | President and CEO |
May 20 '26 |
Sale |
1.88 |
28,946 |
54,482 |
635,762 |
0.05%
0.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):